CAS 145040-37-5|Candesartan cilexetil
| Common Name | Candesartan cilexetil | ||
|---|---|---|---|
| CAS Number | 145040-37-5 | Molecular Weight | 610.660 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 843.3±75.0 °C at 760 mmHg |
| Molecular Formula | C33H34N6O6 | Melting Point | 168-170?C |
| MSDS | ChineseUSA | Flash Point | 463.8±37.1 °C |
| Symbol | GHS08, GHS09 | Signal Word | Warning |
Names
| Name | Candesartan cilexetil |
|---|---|
| Synonym | More Synonyms |
Candesartan cilexetil BiologicalActivity
| Description | Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.Target: Type-1 angiotensin II receptorCandesartan is generally well tolerated and significantly reduced cardiovascular deaths and hospital admissions for heart failure. Ejection fraction or treatment at baseline did not alter these effects [1]. In rats, TCV-116 inhibited the pressor responses to Ang I, Ang II, and Ang III without an effect on the bradykinin (BK)-induced depressor response. In SHR, the antihypertensive effect of TCV-116 (10 mg/kg) was larger than the maximum antihypertensive effect of enalapril and was not intensified by combination with enalapril. TCV-116 is more effective than enalapril in reducing blood pressure in SHR and 1K, 1C-HR, and that the BK- and/or prostaglandin-potentiating effect of enalapril contributes little to its antihypertensive mechanism in SHR [2]. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Angiotensin ReceptorResearch Areas >>Cardiovascular Disease |
| References | [1]. Pfeffer, M.A., et al., Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003. 362(9386): p. 759-66. [2]. Wada, T., et al., Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats. Hypertens Res, 1996. 19(2): p. 75-81. |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 843.3±75.0 °C at 760 mmHg |
| Melting Point | 168-170?C |
| Molecular Formula | C33H34N6O6 |
| Molecular Weight | 610.660 |
| Flash Point | 463.8±37.1 °C |
| Exact Mass | 610.253967 |
| PSA | 143.34000 |
| LogP | 7.79 |
| Vapour Pressure | 0.0±3.1 mmHg at 25°C |
| Index of Refraction | 1.667 |
| InChIKey | GHOSNRCGJFBJIB-UHFFFAOYSA-N |
| SMILES | CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 |
| Storage condition | -20°C Freezer |
Safety Information
| Symbol | GHS08, GHS09 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H361-H400 |
| Precautionary Statements | P280 |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R20/21/22 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| HS Code | 2933990090 |
Customs
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles29
More Articles| Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug. AAPS PharmSciTech 16(1) , 108-17, (2015) The aim of this study was to prepare candesartan cilexetil-loaded niosomes and mixed niosomes to enhance the aqueous solubility of the drug, thus improving its oral bioavailability. The formulations w... | |
| Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan. Acta. Pharm. 64(4) , 463-74, (2014) Available tablets or capsules for adults are often used to prepare extemporaneously formulated medicines appropriate for children. The most acceptable drug forms in pediatric population are oral liqui... | |
| Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs. Drug Metab. Dispos. 42(9) , 1522-31, (2014) Hydrolysis plays an important role in metabolic activation of prodrugs. In the current study, species and in vitro system differences in hepatic and extrahepatic hydrolysis were investigated for 11 pr... |
Synonyms
| 1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}-1H-benzimidazole-7-carboxylate |
| Candesartan cilexetil |
| 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate |
| 2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic Acid 1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl Ester |
| UNII:R85M2X0D68 |
| MFCD00871371 |
| 1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate |
| 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester |
| Candesartan (Cilexetil) |
